文献速递炎症性肠病

炎症性肠病患者对CT-P13与英夫利西单抗原研药的抗原反应显示相似的表位识别

Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition.
PubMed 文献 · Aliment Pharmacol Ther · 2018-06-05

本研究检测了炎症性肠病患者血清中抗CT-P13抗体与英夫利西单抗原研药及CT-P13的交叉反应性,并比较了两者诱发的抗原表位。结果显示所有42份抗CT-P13和37份抗英夫利西单抗原研药血清均分别与原研药和CT-P13交叉反应,抗药抗体浓度(IgG1和IgG4)高度相关(P < 0.001),主要表位识别率在60%-79%患者中且两者无显著差异。结论强烈支持两者具有相似的抗原谱,并指向抗药抗体阴性患者可安全互换。

要点

  • 抗CT-P13与抗英夫利西单抗原研药血清均能交叉识别两种药物。
  • 抗药抗体浓度(IgG1和IgG4)在两种药物间高度相关(P < 0.001)。
  • 主要表位识别率60%-79%,两者无显著差异,支持抗药抗体阴性患者安全互换。

核心结论

  • 结果强烈支持英夫利西单抗原研药与CT-P13具有相似的抗原谱,并指向抗药抗体阴性患者可安全互换。

研究设计与样本

  • 检测炎症性肠病患者血清中可测得的抗CT-P13抗体对5批次英夫利西单抗原研药和CT-P13的交叉反应性。
  • 使用抗药抗体阳性血清比较抗原表位。

主要发现

  • 全部42份抗CT-P13和37份抗英夫利西单抗原研药的炎症性肠病血清分别与英夫利西单抗原研药和CT-P13交叉反应。
  • 针对英夫利西单抗原研药或CT-P13的抗药抗体浓度在IgG1和IgG4上均高度相关(P < 0.001)。
  • 32例炎症性肠病患者的抗CT-P13血清对CT-P13或英夫利西单抗原研药的TNF结合能力发挥相似的功能性抑制,且在五种不同批次CT-P13和英夫利西单抗原研药存在下与CT-P13的结合减少。
  • 抗CT-P13和抗英夫利西单抗原研药的炎症性肠病血清选择性富集英夫利西单抗VH(CDR1和CDR3)及VL结构域(CDR2和CDR3)的噬菌体肽。
  • 血清反应性在60%-79%患者中检测到英夫利西单抗这些区域的主要表位,CT-P13与英夫利西单抗原研药免疫血清间无显著差异。

临床怎么用

  • 作者认为结果指向抗药抗体阴性患者可安全地在英夫利西单抗原研药与CT-P13之间互换。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: To test the cross-immunogenicity of anti-CT-P13 IBD patients' sera to CT-P13/infliximab originator and the comparative antigenicity evoked by CT-P13/infliximab originator sera. METHODS: Sera of patients with IBD with measurable anti-CT-P13 antibodies were tested for their cross-reactivity to 5 batches of infliximab originator and CT-P13. Anti-drug antibody positive sera from treated patients were used to compare antigenic epitopes. RESULTS: All 42 anti-CT-P13 and 37 anti-infliximab originator IBD sera were cross-reactive with infliximab originator and CT-P13 respectively. Concentration of anti-drug antibodies against infliximab originator or CT-P13 were strongly correlated both for IgG1 and IgG4 (P < 0.001). Anti-CT-P13 sera of patients with IBD (n = 32) exerted similar functional inhibition on CT-P13 or infliximab originator TNF binding capacity and showed reduced binding to CT-P13 in the presence of five different batches of CT-P13 and infliximab originator. Anti-CT-P13 and anti-infliximab originator IBD sera selectively enriched phage-peptides from the VH (CDR1 and CDR3) and VL domains (CDR2 and CDR3) of infliximab. Sera reactivity detected major infliximab epitopes in these regions of infliximab in 60%-79% of patients, and no significant differences were identified between CT-P13 and infliximab originator immunogenic sera. Minor epitopes were localised in framework regions of infliximab with reduced antibody reactivity shown, in 30%-50% of patients. Monoclonal antibodies derived from naïve individuals and ADA-positive IBD patients treated with CT-P13 provided comparable epitope specificity to five different batches of CT-P13 and infliximab originator. CONCLUSIONS: These results strongly support a similar antigenic profile for infliximab originator and CT-P13, and point toward a safe switching between the two drugs in anti-drug antibody negative patients.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Goncalves J, Santos M, Acurcio R, et al. Antigenic response to CT-P13 and infliximab originator in inflammatory bowel disease patients shows similar epitope recognition. Aliment Pharmacol Ther. 2018. PMID: 29873091. doi:10.1111/apt.14808

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。